Genesis Therapeutics
PaidUnlock tough protein targets with Genesis Therapeutics’ GEMS and Pearl molecular AI.
About Genesis Therapeutics
Genesis Therapeutics is a biotech leader in molecular AI that unites deep learning and physics-based machine learning in its proprietary GEMS platform and Pearl foundation model to unlock tough protein targets and rapidly discover highly potent, selective small-molecule therapeutics across multiple disease areas. With state-of-the-art protein–ligand prediction, industry-leading speed, and a growing pipeline, Genesis partners with pharma while advancing its own AI-enabled medicines. The company has secured over $256M in funding from top investors including a16z, Fidelity, BlackRock, and NVIDIA, and established major collaborations with Gilead and Incyte (including a $120M upfront expansion).
Key Features
Pros & Cons
- State-of-the-art protein-ligand structure prediction, reportedly outperforming AlphaFold 3
- Proprietary GEMS platform integrates deep learning and physics for efficient molecular design
- Strong partnerships with major pharma (Gilead, Incyte) with significant upfront payments ($65M+ across deals)
- Well-funded with over $256M in total funding from top investors (a16z, Fidelity, BlackRock, NVIDIA)
- Iterative learning loop: each design cycle generates new data to continuously improve AI models
- Focus on difficult, chemically complex targets that are intractable to traditional approaches
- Pricing not publicly disclosed; requires contacting sales (pricing model: contact)
- Internal pipeline details are limited; most progress is demonstrated through partnerships
- Platform complexity may require significant expertise in both AI and drug discovery to adopt
- Relies on proprietary datasets and models, which may limit external validation and reproducibility